UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

             CURRENT REPORT FILED PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

                                 Date of Report
                       (Date of earliest event reported):

                                  July 23, 2003



                                 ANTIGENICS INC.
             (Exact name of registrant as specified in its charter)


           DELAWARE                       000-29089              06-1562417
  (State or other jurisdiction     (Commission file number)   (I.R.S. Employer
of incorporation of organization)                            Identification No.)


                          630 FIFTH AVENUE, SUITE 2100
                            NEW YORK, NEW YORK 10111
              (Address of principal executive offices and zip code)

                                 (212) 994-8200
              (Registrant's telephone number, including area code)








Item 7.    Financial Statements, Pro Forma Financial Statements and Exhibits.

(c) Exhibits:

99.1     Press Release dated July 23, 2003


Item 9.  Regulation FD Disclosure (Information furnished pursuant to Item 12,
         "Disclosure of Results of Operations and Financial Condition").

         On July 23, 2003, Antigenics Inc. announced its financial
         results for the quarter ended June 30, 2003. The full text of
         the press release issued in connection with the announcement
         is attached as Exhibit 99.1 to this current report on Form
         8-K.

         The information in this report on Form 8-K and the Exhibit
         attached hereto is being furnished pursuant to Item 12 of Form
         8-K, Disclosure of Results of Operations and Financial
         Condition, and is presented under Item 9, Regulation FD
         Disclosure, in accordance with the procedural guidance in SEC
         Release No. 33-8216. The information shall not be deemed
         "filed" for purposes of Section 18 of the Securities Exchange
         Act of 1934 (the "Exchange Act") or otherwise subject to the
         liabilities of that section, nor shall it be deemed
         incorporated by reference in any filing under the Securities
         Act of 1933 or the Exchange Act, except as expressly set forth
         by specific reference in such a filing.











                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                                                 ANTIGENICS INC.

Date: July 23, 2003                                      By:  /s/ Garo H. Armen
                                                               -----------------
                                                            Garo H. Armen, Ph.D.
                                            Chairman and Chief Executive Officer













                                  EXHIBIT INDEX


         The following designated exhibits are filed herewith:

         Exhibits:

         99.1                       Press Release dated July 23, 2003